Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery

Diabetes, Obesity and Metabolism

Volumn 16, Issue 12, 2014, Pages 1230-1238

  Malin, S K ^a,b   Bena, J ^a   Abood, B ^a   Pothier, C E ^a   Bhatt, D L ^c   Nissen, S ^a   Brethauer, S A ^a   Schauer, P R ^a   Kirwan, J P ^a,b   Kashyap, S R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diabetes; Gastric bypass; Glycaemic control; Insulin secretion; Obesity; Sleeve gastrectomy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIDIABETIC AGENT; BIGUANIDE; C PEPTIDE; C REACTIVE PROTEIN; FAT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN; LEPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BARIATRIC SURGERY; BODY FAT; BODY MASS; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; PANCREAS ISLET CELL FUNCTION; RANDOMIZED CONTROLLED TRIAL; REMISSION; ROUX EN Y GASTRIC BYPASS; ROUX Y ANASTOMOSIS; STOMACH BYPASS; BLOOD; GASTRECTOMY; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GASTRIC BYPASS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCRETINS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84920466258     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12376     Document Type: Article

References (42)

1. Mingrone G, Panunzi S, De Gaetano A et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-1585.
2. Schauer PR, Bhatt DL, Kirwan JP et al. Bariatric surgery versus intensive medical therapy for diabetes - 3 year outcomes. N Engl J Med 2014; 370: 2002-2013.
3. Peterli R, Steinert RE, Woelnerhanssen B et al. Metabolic and hormonal changes after laparoscopic roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 2012; 22: 740-748.
4. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247: 401-407.
5. Ikramuddin S, Korner J, Lee WJ et al. Roux-en-Y gastric bypass vs. intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial. JAMA 2013; 309: 2240-2249.
6. Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-350.
7. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737.
8. Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese type 2 diabetes. Surg Obes Relat Dis 2011; 7: 433-447.
9. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care 2013; 36(Suppl. 1): S11-S66.
10. Chikunguwo SM, Wolfe LG, Dodson P et al. Analysis of factors associated with durable remission of diabetes after roux-en-Y gastric bypass. Surg Obes Relat Dis 2010; 6: 254-259.
11. Brethauer SA, Aminian A, Romero Talamás H et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013; 258: 628-636.
12. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003; 237: 751-756.
13. Hall TC, Pellen MG, Sedman PC, Jain PK. Preoperative factors predicting remission of type 2 diabetes mellitus after roux-en-Y gastric bypass surgery for obesity. Obes Surg 2010; 20: 1245-1250.
14. DeFronzo RA, Abdul-Ghani MA. Preservation of ß-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 2011; 96: 2354-2366.
15. Malin SK, Finnegan S, Fealy CE, Filion J, Rocco MB, Kirwan JP. β-Cell dysfunction is associated with metabolic syndrome severity in adults. Metab Syndr Relat Disord 2013; 12: 79-85.
16. Appachi SK, Kashyap SR. 'Adiposopathy' and cardiovascular disease: the benefits of bariatric surgery. Curr Opin Cardiol 2013; 28: 540-546.
17. Hirsch FF, Pareja JC, Geloneze SR, Chaim E, Cazzo E, Geloneze B. Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes. Obes Surg 2012; 22: 910-917.
18. Kashyap SR, Bhatt DL, Wolski K et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery vs intensive medical treatment. Diabetes Care 2013; 36: 2175-2182.
19. Malin SK, Samat A, Wolski K et al. Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs. standard medical therapy. Int J Obes 2013; 38: 364-370.
20. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377.
21. Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther 2006; 4: 871-895.
22. Swarbrick MH, Havel JP. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008; 6: 87-102.
23. Chen J, Pamuklar Z, Spagnoli A, Torquati A. Serum leptin levels are inversely correlated with omental gene expression of adiponectin and markedly decreased after gastric bypass surgery. Surg Endosc 2012; 26: 1476-1480.
24. Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 2012; 22: 950-955.
25. Kelly KR, Haus JM, Solomon TPJ et al. A low-glycemic index diet and exercise intervention reduces TNF(alpha) in isolated mononuclear cells of older, obese adults. J Nutr 2011; 141: 1089-1094.
26. Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res 2012; 61: 789-807.
27. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302: 179-188.
28. Turner AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55: 2319-2326.
29. Hagemann D, Holst J, Gethmann A, Banasch M, Schmidt W, Meier JJ. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regul Pept 2007; 143: 64-68.
30. Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011; 7: 683-690.
31. Jimenez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes mellitus after gastric bypass surgery. Diabetes Care 2013; 36: 2062-2069.
32. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007; 3: 597-601.
33. Nannipieri M, Baldi S, Mari A et al. Roux-en Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab 2013; 98: 4391-4399.
34. Habegger KM, Heppner KM, Amburgy SE et al. GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats. Diabetes 2014; 63: 505-513.
35. Dutia R, Brakoniecki K, Bunker P et al. Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission. Diabetes 2014; 63: 1214-1223.
36. Kharroubi I, Rasschaert J, Eizirik DL, Cnop M. Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun 2003; 312: 1118-1122.
37. Okamoto M, Ohara-Imaizumi M, Kubota N et al. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 2008; 51: 827-835.
38. Staiger K, Stefan N, Staiger H et al. Adiponectin is functionally active in human islets but does not affect insulin secretory function or beta-cell lipoapoptosis. J Clin Endocrinol Metab 2005; 90: 6707-6713.
39. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 2004; 27: 547-552.
40. Guldstrand M, Ahrén B, Adamson U. Improved beta-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab 2003; 284: E557-E565.
41. Patane G, Caporaello N, Marchetti P et al. Adiponectin increases glucose-induced insulin secretion through the activation of lipid oxidation. Acta Diabetol 2013; 50: 851-857.
42. Li JF, Lai DD, Ni B, Sun KX. Comparison of laparoscopic Roux-en Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes: a meta-analysis of randomized controlled trials. Can J Surg 2013; 56: E158-E164.